In brief: Peplin, Bone Medical, Probiomics, BioDiem
Monday, 01 August, 2005
Peplin (ASX:PEP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
Bone Medical (ASX:BNE) has appointed BIO-IB as financial advisors to assist with a potential capital raise targeting US institutional investors expected to take place later this year.
Taylor Collison intends to underwrite a $1 million placement of new fully paid ordinary shares in Probiomics (ASX:PCC). A total of 12,500,000 shares will be issued at $0.08 per share and the funds from the placement will be used for working capital.
BioDiem (ASXBDM) has received its second US$1 million milestone payment under its US$8m licence agreement with Akzo Nobel's Nobilon in the development of its novel intranasal flu vaccine.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
